BioSpace News Archive

Amneal Pharmaceuticals, Inc. announced that it will transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) today announced the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older.

Thubrikar Aortic Valve, Inc. today announced authorization from the Competent Authority of Poland to expand the TAVI-1 CE Mark trial of the Optimum Transcatheter Aortic Valve Implantation System™ (Optimum TAVI System™).

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,175 shares of its common stock to sixteen newly-hired employees, with a grant date of December 14, 2023.

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business. During the year, Edesa reported favorable results from two clinical studies and achieved multiple regulatory and operational milestones for its current and upcoming drug de

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 78,576 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 44,900 shares of common stock and inducement restricted stock units, covering an aggregate of 33,676 shares of its common stock.

Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progressed following at least one, but no more than four, prior lines of therapy for metastatic disease will be discontinued due to futility based on a planned analysis conducted by an independent data monitoring committee.

Astellas Pharma Inc. and Pfizer Inc. announced that on December 15, 2023 the U.S. Food and Drug Administration has approved PADCEV® with KEYTRUDA® for the treatment of adult patients with locally advanced or metastatic urothelial cancer.

Tourmaline Bio, Inc. announced that Tourmaline has been added to the NASDAQ Biotechnology Index, effective prior to market open, Monday, December 18, 2023.